Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial
Authors' conclusion
The results of SYNCHRONIZE-JP will provide Japan-specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.
Study context
- Population
- Japanese adults aged ≥18 years with obesity disease: BMI ≥35 kg/m² with ≥1 obesity complication or BMI ≥27 kg/m² with ≥2 obesity complications; ≥1 self-reported unsuccessful dietary effort to lose weight; ≥1 complication being T2D (capped at 30% enrolment), hypertension or dyslipidaemiaenrolled
- Participants
- 274 adults
- Comparison
- Once-weekly survodutide 3.6 or 6.0 mg vs placebo, with reduced-calorie diet and increased physical activity
- Primary endpoint
- Percentage change in body weight and achievement of body weight reduction ≥5% from baseline
- Follow-up
- Week 76
Methodological detailsSYNCHRONIZE-JP, 76-week, double-blind, parallel-group, multi-centre, phase 3, A subset of participants will be assessed for liver fat content and body composition
- SYNCHRONIZE-JP
- 76-week
- Double-blind
- Parallel-group
- Multi-centre
- Phase 3
- A subset of participants will be assessed for liver fat content and body composition
Primary result
As reported in the abstract
Baseline characteristics of enrolled participants
- T2D
- 24.1%
- Mean age
- 53.1 years
- Female
- 47.8%
- Mean BMI
- 33.2 kg/m²
- Dyslipidaemia
- 81.4%
- Hypertension
- 72.6%
- Hyperuricaemia
- 30.3%
- MASLD
- 26.6%
Original publication
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial. Diabetes Obes Metab. Published 31 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →